Skip to main content

Advertisement

SpringerLink
Log in

The Landmark Series: Hilar Cholangiocarcinoma

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Hilar cholangiocarcinoma (HC) is a rare and highly aggressive biliary tract neoplasm. As such, the data driving the management of this disease generally are not based on prospective clinical trial data but rather consist of retrospective experiences and limited level 1 data. Surgical resection offers the best chance of a long-term survival, but local and distant recurrences are common. This report presents landmark articles that form the basis of preoperative, operative, and adjuvant strategies for HC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB Oxford. 2015;17:691–9.

    PubMed  PubMed Central  Google Scholar 

  2. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557–88.

    PubMed  PubMed Central  Google Scholar 

  3. Lidsky ME, Jarnagin WR. Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center. Ann Gastroenterol Surg. 2018;2:304–12.

    PubMed  PubMed Central  Google Scholar 

  4. Groot Koerkamp B, Wiggers JK, Allen PJ, et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection. J Am Coll Surg. 2015;221:1041–9.

    PubMed  PubMed Central  Google Scholar 

  5. Nakeeb A, Pitt HA. Radiation therapy, chemotherapy, and chemoradiation in hilar cholangiocarcinoma. HPB Oxford. 2005;7:278–82.

    PubMed  PubMed Central  Google Scholar 

  6. Cherqui D, Benoist S, Malassagne B, Humeres R, Rodriguez V, Fagniez PL. Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. Arch Surg. 2000;135:302–8.

    CAS  PubMed  Google Scholar 

  7. Iacono C, Ruzzenente A, Campagnaro T, Bortolasi L, Valdegamberi A, Guglielmi A. Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks. Ann Surg. 2013;257:191–204.

    PubMed  Google Scholar 

  8. Kawasaki S, Imamura H, Kobayashi A, Noike T, Miwa S, Miyagawa S. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg. 2003;238:84–92.

    PubMed  PubMed Central  Google Scholar 

  9. Nimura Y, Kamiya J, Kondo S, et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg. 2000;7:155–62.

    CAS  PubMed  Google Scholar 

  10. Kennedy TJ, Yopp A, Qin Y, et al. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB Oxford. 2009;11:445–51.

    PubMed  PubMed Central  Google Scholar 

  11. Wiggers JK, Groot Koerkamp B, Cieslak KP, et al. Postoperative mortality after liver resection for perihilar cholangiocarcinoma: development of a risk score and importance of biliary drainage of the future liver remnant. J Am Coll Surg. 2016;223(321–31):e321.

    Google Scholar 

  12. Gaspersz MP, Buettner S, Roos E, et al. A preoperative prognostic model to predict surgical success in patients with perihilar cholangiocarcinoma. J Surg Oncol. 2018;118:469–76.

    CAS  PubMed  Google Scholar 

  13. She WH, Cheung TT, Ma KW, et al. Defining the optimal bilirubin level before hepatectomy for hilar cholangiocarcinoma. BMC Cancer. 2020;20:914.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Coelen RJS, Roos E, Wiggers JK, et al. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2018;3:681–90.

    PubMed  Google Scholar 

  15. Kang MJ, Choi YS, Jang JY, Han IW, Kim SW. Catheter tract recurrence after percutaneous biliary drainage for hilar cholangiocarcinoma. World J Surg. 2013;37:437–42.

    PubMed  Google Scholar 

  16. Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247:49–57.

    PubMed  Google Scholar 

  17. Leung U, Simpson AL, Araujo RL, et al. Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure. J Am Coll Surg. 2014;219:620–30.

    PubMed  PubMed Central  Google Scholar 

  18. Lang H, de Santibanes E, Schlitt HJ, et al. 10th Anniversary of ALPPS: lessons learned and quo vadis. Ann Surg. 2019;269:114–9.

    PubMed  Google Scholar 

  19. Sakamoto Y, Matsumura M, Yamashita S, Ohkura N, Hasegawa K, Kokudo N. Partial TIPE ALPPS for perihilar cancer. Ann Surg. 2018;267:e18-20.

    PubMed  Google Scholar 

  20. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255:405–14.

    PubMed  Google Scholar 

  21. Olthof PB, Miyasaka M, Koerkamp BG, et al. A comparison of treatment and outcomes of perihilar cholangiocarcinoma between Eastern and Western centers. HPB Oxford. 2019;21:345–51.

    PubMed  Google Scholar 

  22. Jarnagin WR, Bowne W, Klimstra DS, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005;241:703–12; discussion 712–4.

  23. Weber SM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Staging laparoscopy in patients with extrahepatic biliary carcinoma: analysis of 100 patients. Ann Surg. 2002;235:392–9.

    PubMed  PubMed Central  Google Scholar 

  24. Vollmer CM, Drebin JA, Middleton WD, et al. Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg. 2002;235:1–7.

    PubMed  PubMed Central  Google Scholar 

  25. Matsuo K, Rocha FG, Ito K, et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg. 2012;215:343–55.

    PubMed  Google Scholar 

  26. Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258:129–40.

    PubMed  Google Scholar 

  27. Buettner S, Margonis GA, Kim Y, et al. Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. HPB Oxford. 2016;18:510–7.

    PubMed  PubMed Central  Google Scholar 

  28. Komaya K, Ebata T, Yokoyama Y, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018;163:732–8.

    PubMed  Google Scholar 

  29. Kajitani T, Kuno K, Hishida Y. Yamanobe T [Surgery of bile duct cancer at the porta hepatis]. Shujutsu. 1966;20:997–1002.

    CAS  PubMed  Google Scholar 

  30. Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg. 1999;230:808–18; discussion 819.

  31. Neuhaus P, Thelen A, Jonas S, et al. Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol. 2012;19:1602–8.

    PubMed  Google Scholar 

  32. Tsuzuki T, Ogata Y, Iida S, Nakanishi I, Takenaka Y, Yoshii H. Carcinoma of the bifurcation of the hepatic ducts. Arch Surg. 1983;118:1147–51.

    CAS  PubMed  Google Scholar 

  33. Mizuno T, Ebata T, Yokoyama Y, et al. Combined vascular resection for locally advanced perihilar cholangiocarcinoma. Ann Surg. 2020. https://doi.org/10.1097/SLA.0000000000004322.

    Article  PubMed  Google Scholar 

  34. Nagino M, Nimura Y, Nishio H, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg. 2010;252:115–23.

    PubMed  Google Scholar 

  35. Saldinger PF, Blumgart LH. Resection of hilar cholangiocarcinoma: a European and United States experience. J Hepatobiliary Pancreat Surg. 2000;7:111–4.

    CAS  PubMed  Google Scholar 

  36. Endo I, House MG, Klimstra DS, et al. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol. 2008;15:2104–12.

    PubMed  Google Scholar 

  37. Otsuka S, Ebata T, Yokoyama Y, et al. Clinical value of additional resection of a margin-positive distal bile duct in perihilar cholangiocarcinoma. Br J Surg. 2019;106:774–82.

    CAS  PubMed  Google Scholar 

  38. Shinohara K, Ebata T, Shimoyama Y, et al. A study on radial margin status in resected perihilar cholangiocarcinoma. Ann Surg. 2021;273(3):572-8.

    PubMed  Google Scholar 

  39. Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg. 2001;233:385–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Tojima Y, Nagino M, Ebata T, Uesaka K, Kamiya J, Nimura Y. Immunohistochemically demonstrated lymph node micrometastasis and prognosis in patients with otherwise node-negative hilar cholangiocarcinoma. Ann Surg. 2003;237:201–7.

    PubMed  PubMed Central  Google Scholar 

  41. Ito K, Ito H, Allen PJ, et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg. 2010;251:675–81.

    PubMed  Google Scholar 

  42. Iwatsuki S, Todo S, Marsh JW, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg. 1998;187:358–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Klempnauer J, Ridder GJ, Werner M, Weimann A, Pichlmayr R. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer. 1997;79:26–34.

    CAS  PubMed  Google Scholar 

  44. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. 2000;69:1633–7.

    CAS  PubMed  Google Scholar 

  45. Robles R, Figueras J, Turrion VS, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg. 2004;239:265–71.

    PubMed  PubMed Central  Google Scholar 

  46. Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004;24:201–7.

    PubMed  Google Scholar 

  47. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451–8; discussion 458–61.

  48. Anderson B, Doyle MBM. Surgical considerations of hilar cholangiocarcinoma. Surg Oncol Clin North Am. 2019;28:601–17.

    Google Scholar 

  49. Heimbach JK, Sanchez W, Rosen CB, Gores GJ. Transperitoneal fine-needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB Oxford. 2011;13:356–60.

    PubMed  PubMed Central  Google Scholar 

  50. Croome KP, Rosen CB, Heimbach JK, Nagorney DM. Is liver transplantation appropriate for patients with potentially resectable de novo hilar cholangiocarcinoma? J Am Coll Surg. 2015;221:130–9.

    PubMed  Google Scholar 

  51. Ethun CG, Lopez-Aguiar AG, Anderson DJ, et al. Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann Surg. 2018;267:797–805.

    PubMed  Google Scholar 

  52. De Vreede I, Steers JL, Burch PA, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 2000;6:309–16.

    PubMed  Google Scholar 

  53. Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB Oxford. 2008;10:186–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Nakahashi K, Ebata T, Yokoyama Y, et al. How long should follow-up be continued after R0 resection of perihilar cholangiocarcinoma? Surgery. 2020;168:617–24.

    PubMed  Google Scholar 

  55. Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192–202.

    CAS  PubMed  Google Scholar 

  56. Kobayashi A, Miwa S, Nakata T, Miyagawa S. Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg. 2010;97:56–64.

    CAS  PubMed  Google Scholar 

  57. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–95.

    PubMed  Google Scholar 

  58. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.

    CAS  PubMed  Google Scholar 

  59. Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37:658–67.

    CAS  PubMed  Google Scholar 

  60. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–73.

    CAS  PubMed  Google Scholar 

  61. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37:1015–27.

    PubMed  Google Scholar 

  62. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–700.

    PubMed  Google Scholar 

  63. Cameron JL, Pitt HA, Zinner MJ, Kaufman SL, Coleman J. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg. 1990;159:91–7; discussion 97–8.

  64. Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg. 1995;221:788–97; discussion 797–8.

  65. Borghero Y, Crane CH, Szklaruk J, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008;15:3147–56.

    PubMed  Google Scholar 

  66. Kamada T, Saitou H, Takamura A, Nojima T, Okushiba SI. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys. 1996;34:767–74.

    CAS  PubMed  Google Scholar 

  67. Kim TH, Han SS, Park SJ, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys. 2011;81:e853–9.

    PubMed  Google Scholar 

  68. Nakeeb A, Comuzzie AG, Martin L, et al. Gallstones: genetics versus environment. Ann Surg. 2002;235:842–9.

    PubMed  PubMed Central  Google Scholar 

  69. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33:2617–22.

    CAS  PubMed  Google Scholar 

  70. Nakachi K, Konishi M, Ikeda M, et al. A randomized Phase III trial of adjuvant S-1 therapy vs observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol. 2018;48(4):392–5.

    PubMed  Google Scholar 

  71. Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial): a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;15:564.

    PubMed  PubMed Central  Google Scholar 

  72. Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24:4154–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Atanasov G, Hau HM, Dietel C, et al. Prognostic significance of macrophage invasion in hilar cholangiocarcinoma. BMC Cancer. 2015;15:790.

    PubMed  PubMed Central  Google Scholar 

  74. Silva VW, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol. 2016;5:62.

    PubMed  Google Scholar 

  75. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463–73; discussion 473–4.

  76. Launois B, Reding R, Lebeau G, Buard JL. Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg. 2000;7:128–34.

    CAS  PubMed  Google Scholar 

  77. Lee SG, Lee YJ, Park KM, Hwang S, Min PC. One hundred and eleven liver resections for hilar bile duct cancer. J Hepatobiliary Pancreat Surg. 2000;7:135–41.

    CAS  PubMed  Google Scholar 

  78. Gerhards MF, van Gulik TM, de Wit LT, Obertop H, Gouma DJ. Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma: a single-center experience. Surgery. 2000;127:395–404.

    CAS  PubMed  Google Scholar 

  79. Nishio H, Nagino M, Nimura Y. Surgical management of hilar cholangiocarcinoma: the Nagoya experience. HPB Oxford. 2005;7:259–62.

    PubMed  PubMed Central  Google Scholar 

  80. Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. J Hepatobiliary Pancreat Sci. 2010;17:449–54.

    PubMed  Google Scholar 

  81. Unno M, Katayose Y, Rikiyama T, et al. Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2010;17:463–9.

    PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Erin Patterson for her editorial assistance.

Author information

Authors and Affiliations

  1. Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Kevin C. Soares MD & William R. Jarnagin MD

  2. Department of Surgery, Weill Cornell Medical College, New York, NY, USA

    Kevin C. Soares MD & William R. Jarnagin MD

Authors
  1. Kevin C. Soares MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William R. Jarnagin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William R. Jarnagin MD.

Ethics declarations

Disclosure

There are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soares, K.C., Jarnagin, W.R. The Landmark Series: Hilar Cholangiocarcinoma. Ann Surg Oncol 28, 4158–4170 (2021). https://doi.org/10.1245/s10434-021-09871-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-09871-6

Search

Navigation